Usage patterns of 'over-the-counter' vs. prescription-strength nonsteroidal anti-inflammatory drugs in France

British Journal of Clinical Pharmacology

Volumn 77, Issue 5, 2014, Pages 887-895

  Duong, Mai ^a   Salvo, Francesco ^c,d   Pariente, Antoine ^a,b,c   Abouelfath, Abdelilah ^b   Lassalle, Regis ^b   Droz, Cecile ^a,b   Blin, Patrick ^b   Moore, Nicholas ^a,b,c  

^a INSERM U657   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

drug related risks; over the counter nonsteroidal anti inflammatory drugs; prescription nonsteroidal anti inflammatory drugs; usage patterns

Indexed keywords

ANTILIPEMIC AGENT; CARDIOVASCULAR AGENT; DICLOFENAC; FENOPROFEN; IBUPROFEN; KETOPROFEN; MEFENAMIC ACID; NAPROXEN; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PRESCRIPTION DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DRUG USE; FEMALE; FRANCE; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; DRUG UTILIZATION; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG UTILIZATION; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; NONPRESCRIPTION DRUGS;

EID: 84899084301     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12239     Document Type: Article

References (51)

1. Henry D, Dobson A, Turner C,. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993; 105: 1078-1088.
2. Henry D, Lim LL, Garcia Rodriguez LA, Perez Gutthann S, Carson JL, Griffin M, Savage R, Logan R, Moride Y, Hawkey C, Hill S, Fries JT,. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563-1566.
3. Henry D, McGettigan P,. Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs. Int J Clin Pract 2003; (Suppl. 135): 43-49.
4. de Abajo FJ, Garcia Rodriguez LA,. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol 2001; 1: 1.
5. Garcia Rodriguez LA, Barreales Tolosa L,. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 2007; 132: 498-506.
6. Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, Gonzalez-Perez A,. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004; 109: 3000-3006.
7. Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA,. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006; 98: 266-274.
8. Varas-Lorenzo C, Maguire A, Castellsague J, Perez-Gutthann S,. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level. Pharmacoepidemiol Drug Saf 2007; 16: 366-376.
9. Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Castellsague J, Pariente A, Scotti L, Sturkenboom M, Perez-Gutthann S,. Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol Drug Saf 2011; 20: 1225-1236.
10. McGettigan P, Henry D,. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011; 8: e1001098.
11. Garcia Rodriguez LA, Tacconelli S, Patrignani P,. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008; 52: 1628-1636.
12. Depont F, Fourrier A, Merliere Y, Droz C, Amouretti M, Begaud B, Benichou J, Moride Y, Blin P, Moore N,. The CADEUS study: methods and logistics. Pharmacoepidemiol Drug Saf 2007; 16: 571-580.
13. Tramer MR, Moore RA, Reynolds DJ, McQuay HJ,. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000; 85: 169-182.
14. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS,. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-1255.
15. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ,. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528, 2 p following 28.
16. Moore N,. Comment on 'Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use' Tramer et al. Pain 2000; 85: 169-182. Pain 2001; 91: 401-2.
17. Laharie D, Droz-Perroteau C, Benichou J, Amouretti M, Blin P, Begaud B, Guiard E, Dutoit S, Lamarque S, Moride Y, Depont F, Fourrier-Reglat A, Moore N,. Hospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users. Br J Clin Pharmacol 2010; 69: 295-302.
18. Moore N,. Place of OTC analgesics and NSAIDs in osteoarthritis. Inflammopharmacology 2003; 11: 355-362.
19. Moore N, Van Ganse E, Le Parc J, Wall R, Schneid H, Farhan M, Verrière F, Pelen F,. The PAIN study: paracetamol, aspirin and ibuprofen new tolerability study. A large scale, randomized clinical trial comparing the tolerability of aspirin, ibuprofen and paracetamol for short-term analgesia. Clin Drug Invest 1999; 18: 89-98.
20. Layton D, Sinclair HK, Bond CM, Hannaford PC, Shakir SA,. Pharmacovigilance of over-the-counter products based in community pharmacy: methodological issues from pilot work conducted in Hampshire and Grampian, UK. Pharmacoepidemiol Drug Saf 2002; 11: 503-513.
21. Porteous T, Bond C, Hannaford P, Sinclair H,. How and why are non-prescription analgesics used in Scotland? Fam Pract 2005; 22: 78-85.
22. Sinclair H, Bond C, Hannaford P,. Over-the-counter ibuprofen: how and why is it used? Int J Pharm Pract 2000; 8: 121-127.
23. Sinclair HK, Bond CM, Hannaford PC,. Long term follow-up studies of users of nonprescription medicines purchased from community pharmacies: some methodological issues. Drug Saf 2001; 24: 929-938.
24. Urquhart G, Sinclair HK, Hannaford PC,. The use of non-prescription medicines by general practitioner attendees. Pharmacoepidemiol Drug Saf 2004; 13: 773-779.
25. Hasford J, Moore N, Hoye K,. Safety and usage pattern of low-dose diclofenac when used as an over-the-counter medication: results of an observational cohort study in a community-based pharmacy setting. Int J Clin Pharmacol Ther 2004; 42: 415-422.
26. Moore N, Gulmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, Jove J, Pariente A, Blin P, Benichou J, Begaud B,. Choice of the denominator in case population studies: event rates for registration for liver transplantation after exposure to NSAIDs in the SALT study in France. Pharmacoepidemiol Drug Saf 2013; 22: 160-167.
27. Martin-Latry K, Begaud B,. Pharmacoepidemiological research using French reimbursement databases: yes we can! Pharmacoepidemiol Drug Saf 2010; 19: 256-265.
28. Blin P, Lassalle R, Dureau-Pournin C, Ambrosino B, Bernard MA, Abouelfath A, Gin H, Le Jeunne C, Pariente A, Droz C, Moore N,. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia 2012; 55: 644-653.
29. Fosbol EL, Gislason GH, Jacobsen S, Abildstrom SZ, Hansen ML, Schramm TK, Folke F, Sorensen R, Rasmussen JN, Kober L, Madsen M, Torp-Pedersen C,. The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people. Pharmacoepidemiol Drug Saf 2008; 17: 822-833.
30. Moore N, Diris H, Martin K, Viale R, Fourrier A, Moride Y, Begaud B,. NSAID use profiles derived from reimbursement data in France. Therapie 2004; 59: 541-546.
31. Moore N, Verschuren X, Montout C, Callens J, Kong SX, Begaud B,. Excess costs related to non-steroidal anti-inflammatory drug utilization in general practice. Therapie 2000; 55: 133-136.
32. Depont F, Fourrier A, Merliere Y, Droz C, Amouretti M, Begaud B, Benichou J, Moride Y, Velo GP, Sturkenboom M, Blin P, Moore N,. Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study. Pharmacoepidemiol Drug Saf 2007; 16: 891-900.
33. Fourrier-Reglat A, de Bailliencourt S, Molimard M, Latry P, Moore N, Peter C, Begaud B,. [Celecoxib prescription: data from the 'Securite Sociale' database of the Aquitaine Region, South-Western, France]. Therapie 2005; 60: 25-29.
34. Bhagat K,. Effects of non-steroidal anti-inflammatory drugs on hypertension control using angiotensin converting enzyme inhibitors and thiazide diuretics. East Afr Med J 2001; 78: 507-509.
35. Houston MC, Weir M, Gray J, Ginsberg D, Szeto C, Kaihlenen PM, Sugimoto D, Runde M, Lefkowitz M,. The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Intern Med 1995; 155: 1049-1054.
36. Minuz P, Lechi A, Arosio E, Degan M, Capuzzo MG, Lechi C, Corsato M, Dalla Riva A, Velo GP,. Antihypertensive activity of enalapril. Effect of ibuprofen and different salt intakes. J Clin Hypertens 1987; 3: 645-653.
37. Palmer R, Weiss R, Zusman RM, Haig A, Flavin S, MacDonald B,. Effects of nabumetone, celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors. Am J Hypertens 2003; 16: 135-139.
38. Lee A, Cooper MG, Craig JC, Knight JF, Keneally JP,. The effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on postoperative renal function: a meta-analysis. Anaesth Intensive Care 1999; 27: 574-580.
39. Furey SA, Vargas R, McMahon FG,. Renovascular effects of nonprescription ibuprofen in elderly hypertensive patients with mild renal impairment. Pharmacotherapy 1993; 13: 143-148.
40. Murray MD, Black PK, Kuzmik DD, Haag KM, Manatunga AK, Mullin MA, Hall SD, Brater DC,. Acute and chronic effects of nonsteroidal antiinflammatory drugs on glomerular filtration rate in elderly patients. Am J Med Sci 1995; 310: 188-197.
41. Gurwitz JH, Everitt DE, Monane M, Glynn RJ, Choodnovskiy I, Beaudet MP, Avorn J,. The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons. J Gerontol A Biol Sci Med Sci 1996; 51: M74-79.
42. Thakur V, Cook ME, Wallin JD,. Antihypertensive effect of the combination of fosinopril and HCTZ is resistant to interference by nonsteroidal antiinflammatory drugs. Am J Hypertens 1999; 12: 925-928.
43. Pope JE, Anderson JJ, Felson DT,. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993; 153: 477-484.
44. Wolfe MM, Lichtenstein DR, Singh G,. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340: 1888-1899.
45. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C,. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332: 1302-1308.
46. Salpeter SR, Gregor P, Ormiston TM, Whitlock R, Raina P, Thabane L, Topol EJ,. Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. Am J Med 2006; 119: 552-559.
47. Salvo F, Fourrier-Reglat A, Bazin F, Robinson P, Riera-Guardia N, Haag M, Caputi AP, Moore N, Sturkenboom MC, Pariente A,. Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials. Clin Pharmacol Ther 2011; 89: 855-866.
48. Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Castellsague J, Salvo F, Nicotra F, Sturkenboom M, Perez-Gutthann S,. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf 2013. doi: 10.1002/pds.3437.
49. Gulmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, Jove J, Gatta A, McCormick PA, Metselaar HJ, Monteiro E, Thorburn D, Bernal W, Zouboulis-Vafiadis I, de Vries C, Perez-Gutthann S, Sturkenboom M, Benichou J, Montastruc JL, Horsmans Y, Salvo F, Hamoud F, Micon S, Droz-Perroteau C, Blin P, Moore N,. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. Drug Saf 2013; 36: 135-144.
50. Noize P, Bazin F, Dufouil C, Lechevallier-Michel N, Ancelin ML, Dartigues JF, Tzourio C, Moore N, Fourrier-Reglat A,. Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three-City (3C) Study. Pharmacoepidemiol Drug Saf 2009; 18: 310-319.
51. Noize P, Bazin F, Pariente A, Dufouil C, Ancelin ML, Helmer C, Moore N, Fourrier-Reglat A,. Validity of chronic drug exposure presumed from repeated patient interviews varied according to drug class. J Clin Epidemiol 2012; 65: 1061-1068.